Anti-MET antibodies and methods of use thereof

US11884734B2 · kind B2 · utility

Assignee

• Celldex Therapeutics, Inc. · US

Inventors

• Yan Yang · Mamaroneck, US
• Sreekala Mandiyan · Bloomfield, US
• Brett Robinson · Mesa, US
• Lida Kimmel · Chester, US
• Yaron R. Hadari · Harrison, US
• Timothy David Jones · Babraham, GB
• Francis Joseph Carr · Aberdeen, GB
• Robert George Edward Holgate · Royston, GB
• Richard Weldon · Wädenswil, CH

Key dates

• Filing date: Sep 15, 2020
• Grant date: Jan 30, 2024
• Expiry date: Dec 16, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/77
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. In one aspect, provided herein is a monoclonal antibody or antigen-binding fragment thereof that binds to the Sema/PSI domain of human MET. Also provided herein is a kit comprising an antibody or antigen-binding fragment provided herein. Also provided herein is a method of managing, protecting against, or treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment provided herein.